Search Results - AGOROPOULOU, C

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

    Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study by Devonshire, Virginia, MD, Havrdova, Eva, MD, Radue, Ernst Wilhelm, Prof, O'Connor, Paul, MD, Zhang-Auberson, Lixin, MD, Agoropoulou, Catherine, PhD, Häring, Dieter Adrian, PhD, Francis, Gordon, MD, Kappos, Ludwig, Prof

    Published in Lancet neurology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Gene structure and expression of the Corynebacterium flavum N13 ask-asd operon

    Gene structure and expression of the Corynebacterium flavum N13 ask-asd operon by FOLLETTIE, M. T, PEOPLES, O. P, AGOROPOULOU, C, SINSKEY, A. J

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Fingolimod (FTY720) oral for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Study design of the phase 3 FORCIDP trial

    Fingolimod (FTY720) oral for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Study design of the phase 3 FORCIDP trial by Hughes, R., Dalakas, M., Latov, N., Léger, J.-M., Merkies, I., Nobile-Orazio, E., Agoropoulou, C., Häring, D.A., Zhang-Auberson, L., von Rosenstiel, P., Hartung, H.-P.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    F ingolimod (FTY720) or al for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy ( CIDP ): Study design of the phase 3 FORCIDP trial

    F ingolimod (FTY720) or al for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy ( CIDP ): Study design of the phase 3 FORCIDP trial by Hughes, R, Dalakas, M, Latov, N, Léger, J.-M, Merkies, I, Nobile-Orazio, E, Agoropoulou, C, Häring, D.A, Zhang-Auberson, L, von Rosenstiel, P, Hartung, H.-P

    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Oral fingolimod (FTY720) in relapsing-remitting multiple sclerosis: baseline patient demographics and disease characteristics from a 2-year phase III trial (FREEDOMS)

    Oral fingolimod (FTY720) in relapsing-remitting multiple sclerosis: baseline patient demographics and disease characteristics from a 2-year phase III trial (FREEDOMS) by Kappos, L, Polman, CH, Radue, E-W, O'Connor, P, Calabresi, P A, Hohlfeld, R, Agoropoulou, C, Pohlmann, H, de Vera, A

    Published in Multiple sclerosis
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: